# Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

> **NCT02903914** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 260 (actual)

## Conditions studied

- Metastatic Cancer
- Solid Tumors
- Colorectal Cancer (CRC)
- Gastric Cancer
- Head and Neck Cancer
- Lung Cancer
- Renal Cell Carcinoma (RCC)
- Bladder Cancer
- UC (Urothelial Cancer)
- Mesothelioma

## Interventions

- **DRUG:** INCB001158
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02903914
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-14
- **Primary completion:** 2020-04-30
- **Final completion:** 2022-08-15
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02903914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02903914, "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02903914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*